Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2229–2239. doi: 10.1158/1055-9965.EPI-14-0491

Table 5.

Grouping by APASL treatment guidelines (among HBsAg positive individuals with HBV DNA, ALT, and HBeAg)

All Asian
Countries
(n=1,113)
Korea
(n=125)
Gyeonggi
Province
(n=53)
Non-
Gyeonggi
Province
(n=56)
Malaysia
(n=34)
China
(n=927)
Fujian
Province
(n=641)
Non-Fujian
Province
(n=206)

HBV DNA ≥ 100,000 and ALT >2xULN 124 (11.2) 15 (12.0) 6 (11.3) 7 (12.5) 2 (5.9) 105 (11.3) 75 (11.7) 16 (7.8)
HBeAg- and VL between 10,000 - 99,999 and ALT >2xULN 88 (7.9) 11 (8.8) 8 (15.1) 2 (3.6) 7 (20.6) 65 (7.0) 43 (6.7) 13 (6.3)
HBV DNA <10,000 654 (58.9) 823 (65.6) 32 (60.4) 40 (71.4) 19 (55.9) 541 (76.1) 367 (57.3) 128 (62.1)